BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38272453)

  • 21. A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
    Merrill MH; Dahi PB; Redd RA; McDonough MM; Chen YB; DeFilipp Z; Herrera AF; Fisher DC; LaCasce AS; Odejide OO; Ng SY; Jacobson CA; Merryman RW; Kim AI; Nieto YL; Sauter CS; Shah GL; Zain JM; Armand P; Jacobsen ED
    Blood; 2023 Aug; 142(7):621-628. PubMed ID: 37319432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome.
    Yang DH; Kim WS; Kim SJ; Bae SH; Kim SH; Kim IH; Yoon SS; Mun YC; Shin HJ; Chae YS; Kwak JY; Kim H; Kim MK; Kim JS; Won JH; Lee JJ; Suh CW
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):118-25. PubMed ID: 19135950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of autologous hematopoietic stem cell transplantation for patients with peripheral T-cell lymphoma in China: A propensity score-matched analysis.
    Gao H; Wu M; Hu S; Ding N; Ji X; Mi L; Wang X; Song Y; Zhu J; Liu W
    Front Oncol; 2022; 12():1039888. PubMed ID: 36465366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
    Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
    Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Up-front autologous hematopoietic stem cell transplantation after first complete remission improved prognosis of advanced extra-nodal NKT cell lymphoma: A multicenter real-world study in China.
    Gao H; Lin N; Gu Z; Zhao S; Wang X; Yuan S; Song Y; Zhu J; Huang W; Liu W; Gao C
    Eur J Haematol; 2023 Jun; 110(6):680-687. PubMed ID: 36825748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of ex vivo purging with CD34+ selection to maximize the effects of autologous stem cell transplantation in peripheral T-cell lymphoma patients.
    Jeon Y; Kim TY; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Cytotherapy; 2023 Dec; 25(12):1307-1316. PubMed ID: 37542512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases.
    Kim HJ; Bang SM; Lee J; Kwon HC; Suh C; Kim HJ; Lee JH; Ryoo BY; Park YH; Kwon JM; Oh SY; Lee HR; Kim K; Jung CW; Park K; Kim WS
    Bone Marrow Transplant; 2006 May; 37(9):819-24. PubMed ID: 16547486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy.
    Huang Z; Li Z; Wang J; Gui R; Zu Y; Yu F; Lin Q; Zhao H; Zhang Y; Fang B; Liu Y; Zhou K; Li Y; Fu Y; Yao Z; Song Y; Zhou J
    Front Oncol; 2023; 13():1162413. PubMed ID: 37256185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group.
    Rodríguez J; Conde E; Gutiérrez A; Arranz R; León A; Marín J; Bendandi M; Albo C; Caballero MD;
    Eur J Haematol; 2007 Jul; 79(1):32-8. PubMed ID: 17598836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
    Martínez C; de Haro ME; Romero S; Gutiérrez A; Domingo-Domènech E; González-Rodríguez AP; Zeberio I; Martínez-Badas MP; Rodríguez-Izquierdo A; Carpio C; Bastos-Oreiro M; Hernández-Rivas JÁ; Vallansot R; Kelleher N; Díaz-Gálvez FJ; Torrado T; Pereira A; García-Sanz R;
    Ann Hematol; 2023 Feb; 102(2):429-437. PubMed ID: 36370191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
    Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
    Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.
    Brink M; Meeuwes FO; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer LH; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Plattel W; Huls GA; Vermaat JSP; Nijland M
    Blood; 2022 Sep; 140(9):1009-1019. PubMed ID: 35544601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.
    Wullenkord R; Berning P; Niemann AL; Wethmar K; Bergmann S; Lutz M; Schliemann C; Mesters R; Keßler T; Schmitz N; Berdel WE; Lenz G; Stelljes M
    Ann Hematol; 2021 Nov; 100(11):2733-2744. PubMed ID: 34477953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
    Kaddu-Mulindwa D; Gödel P; Kutsch N; Heger JM; Scheid C; Borchmann P; Holtick U; Held G; Thurner L; Bewarder M; Rixecker T; Bittenbring JT
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e498-e506. PubMed ID: 35094950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma.
    Kelta M; Zekri J; Abdelghany E; Rehman JU; Khan ZA; Al-Saadi R; Dada R
    Tumori; 2018 Dec; 104(6):471-475. PubMed ID: 28009428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Hill BT; Rybicki LA; Urban TA; Lucena M; Jagadeesh D; Gerds AT; Dean RM; Sobecks RM; Pohlman B; Bolwell B; Kalaycio ME; Hamilton BK; Copelan EA; Majhail NS
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):262-271. PubMed ID: 31610237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.